A four-week Phase IIa, randomized, double-blind, placebocontrolled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in subjects with anemia associated with chronic kidney disease who are not taking recombinant human erythropoietin and are not undergoing dialysis
Latest Information Update: 17 Jul 2023
At a glance
- Drugs Daprodustat (Primary)
- Indications Anaemia; Kidney disorders
- Focus Therapeutic Use
- Sponsors Glaxo Research and Development Ltd.; GlaxoSmithKline; GSK
- 04 Feb 2014 New trial record